Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Publication · Mar 2026
Long-term durability of acoramidis efficacy: OLE of ATTRibute-CM
Publication · Feb 2026
Acoramidis in ATTR-CM: expanding evidence from ATTRibute-CM
Publication · Feb 2026
Impact of acoramidis on clinical stability: ATTRibute-CM (Bayer/BridgeBio)
Publication · Dec 2025
A plain language review of the ATTRibute-CM study from NEJM
Publication · Nov 2025
Efficacy of acoramidis in wild-type and variant ATTR-CM: ATTRibute-CM and OLE
Publication · Sep 2025
Effect of acoramidis on recurrent and cumulative CV outcomes: ATTRibute-CM
Publication · Aug 2025
Contemporary oral medication use and frequency in ATTR-CM
Publication · Jul 2025